A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Crohn's Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy
Latest Information Update: 05 Jul 2025
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms U-EMPOWER
- Sponsors AbbVie
Most Recent Events
- 27 Nov 2024 Planned End Date changed from 20 Dec 2034 to 1 Dec 2034.
- 27 Nov 2024 Planned primary completion date changed from 15 Jun 2027 to 1 Jun 2027.
- 23 Jul 2024 Status changed from not yet recruiting to recruiting.